BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer

NCT01121406 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

110

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Neoplasms

Interventions

DRUG: Paclitaxel
DRUG: Gemcitabine
DRUG: Topotecan
DRUG: Pegylated liposomal doxorubicin (PLD)
DRUG: BI 6727

Sponsor

Boehringer Ingelheim